Crizotinib versus platinum‐based double‐agent chemotherapy as the first line treatment in advanced anaplastic lymphoma kinase‐positive lung adenocarcinoma

Zhang, Quan; Qin, Na; Wang, Jinghui; Lv, Jialin; Yang, Xinjie; Li, Xi; Nong, Jingying; Zhang, Hui; Zhang, Xinyong; Wu, Yi‐Long; Zhang, Shucai

doi:10.1111/1759-7714.12264

Cited by 15 publications

(11 citation statements)

References 16 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The details of our search results could be seen in the flow diagram (Figure 1 ). Among these 13 studies (including 11 non randomized control trials [NRCTs] and 2 randomized control trials [RCTs]), 3 studies described first-line therapies [ 7 , 16 , 17 ], 3 studies described second-line therapies [ 6 , 11 , 16 ] and 7 studies described mixed therapies [ 5 , 10 , 12 – 15 , 19 ]. Moreover, 8 studies reported median PFS and 95% CI [ 5 – 7 , 10 , 13 , 15 , 16 , 19 ].…”

Section: Resultsmentioning

confidence: 99%

Is there a benefit of first- or second-line crizotinib in locally advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer? a meta-analysis

Lin

Zhu

et al. 2016

Oncotarget

View full text Add to dashboard Cite

BackgroundCrizotinib show a promising efficacy in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). However, differences in efficacy for first- and second-line crizotinib are unclear.ResultsThe pooled overall response rate and progression-free survival were 65% and 9.38 months, respectively. In the subgroup analysis, first-line crizotinib showed a higher trend of overall response rate and longer trend of progression-free survival although there was no statistical difference between first-line and second-line crizotinib (74%, 11.28 months vs. 65%, 8.12 months, respectively; fixed effects model). Moreover, overall response rate between Asians and Caucasians were similar (67% and 66%, respectively; fixed effects model).Materials and MethodsA comprehensive search of MEDLINE, EMBASE, WEB OF SCIENCE and the COCHRANE databases from their inception to February 2016 was performed to identify clinical trials in English-language journals. Pooled overall response rate, progression-free survival and differences between first- and second-line crizotinib were estimated. Moreover, overall response rate between Asians and Caucasians were also estimated.ConclusionsFirst-line crizotinib may more effective than second-line crizotinib for patients with locally advanced or metastatic ALK-positive NSCLC.

show abstract

Section: Resultsmentioning

confidence: 99%

Is there a benefit of first- or second-line crizotinib in locally advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer? a meta-analysis

Lin

Zhu

et al. 2016

Oncotarget

View full text Add to dashboard Cite

show abstract

“…A wide variety of studies have shown that the ALK-targeted inhibitor crizotinib produces a prominent positive effect in patients harboring an ALK rearrangement [14,15]. In January 2013, crizotinib was approved by the Sino Food and Drug Administration (SFDA) in mainland China for patients with ALK -positive NSCLC.…”

Section: Introductionmentioning

confidence: 99%

Clinicopathological Features and Therapeutic Responses of Chinese Patients with Advanced Lung Adenocarcinoma Harboring an Anaplastic Lymphoma Kinase Rearrangement

et al. 2017

View full text Add to dashboard Cite

Background: Presence of anaplastic lymphoma kinase (ALK) rearrangement is an indication for crizotinib in the treatment of patients with advanced or metastatic lung adenocarcinoma. Here, we sought to elucidate the association between clinicopathological features and ALK rearrangement status in Chinese patients with advanced lung adenocarcinoma harboring an ALK rearrangement. Patients and Methods:ALK rearrangement status was determined using immunohistochemistry (IHC) in tumor tissues from 120 patients with advanced lung adenocarcinoma, and further assessed by fluorescence in situ hybridization (FISH) assay. The associations between ALK rearrangement status and clinicopathological features were analyzed. Results: According to IHC testing, the ALK-positive rate among the advanced lung adenocarcinoma patients was 6.67% (8/120). FISH validation found 5 patients with ALK rearrangement among the 8 IHC-positive cases. No significant difference was observed regarding age, sex, or smoking status between FISH-positive and -negative patients (p > 0.05). None of the 5 FISH-positive patients benefited from first-line chemotherapy. Conclusion: IHC can be used as a reliable method for ALK rearrangement screening in patients with lung adenocarcinoma, but further FISH validation is imperative. Presence of ALK rearrangement predicts a more aggressive biological behavior of the tumor and might be indicative of poor response to chemotherapy.

show abstract

“…[4]Ceritinib1021000000000Cui, S. [17]Crizotinib72103000500000Felip, E. [5]Ceritinib124NA17NANANANANANANANANAMok, T. [6]Ceritinib1406422NANANA698NANANACui, S. [18]Crizotinib5682000500000Kim, D. W. [7]Ceritinib24612573010121115150816Ou, Sai-Hong [8]Alectinib138382NA411100NANAShaw, A. T. [9]Alectinib87355130000000Zhang, Q. [19]Crizotinib711000000000 NA not available …”

Section: Resultsmentioning

confidence: 99%

Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC

Zhu

Weng

et al. 2017

BMC Cancer

View full text Add to dashboard Cite

BackgroundThe anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-TKIs) have been administered to patients with ALK-positive non-small cell lung cancer for a long period of time and show a promising response. However, the differences in the toxicity profiles among these drugs are still unclear.MethodsWe performed a comprehensive search of the MEDLINE, EMBASE, WEB OF SCIENCE and COCHRANE databases from the drugs’ inception to May 2016 to identify clinical trials. Severe adverse events (AEs) (grade ≥ 3) based on the ALK-TKI type were analysed.ResultsSeventeen trials published between 2011 and 2016, including a total of 1826 patients, were eligible for analysis. Patients in 10 trials (n = 1000) received crizotinib, patients in 5 trials (n = 601) received ceritinib and patients in 2 trials (n = 225) received alectinib. The overall frequencies of treatment-related death and AEs due to treatment withdrawal were 0.9% (12/1365) and 5.5% (85/1543), respectively. Moreover, the frequency of severe AEs in patients treated with ceritinib was significantly higher than patients treated with crizotinib or alectinib, especially for hepatotoxicity, fatigue and some of gastrointestinal symptoms. Additionally, significant difference in the elevated lipase and amylase levels (grade ≥ 3) were detected between ceritinib and crizotinib/alectinib, whereas neutropenia was less frequent.ConclusionsALK-TKIs were safe for ALK-positive patients. Moreover, statistically significant differences in some severe AEs among ceritinib, crizotinib and alectinib were detected in present study.Electronic supplementary materialThe online version of this article (doi:10.1186/s12885-017-3405-3) contains supplementary material, which is available to authorized users.

show abstract

Crizotinib versus platinum‐based double‐agent chemotherapy as the first line treatment in advanced anaplastic lymphoma kinase‐positive lung adenocarcinoma

Cited by 15 publications

References 16 publications

Is there a benefit of first- or second-line crizotinib in locally advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer? a meta-analysis

Is there a benefit of first- or second-line crizotinib in locally advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer? a meta-analysis

Clinicopathological Features and Therapeutic Responses of Chinese Patients with Advanced Lung Adenocarcinoma Harboring an Anaplastic Lymphoma Kinase Rearrangement

Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC

Contact Info

Product

Resources

About